BELLINI: a renaissance for an era of precision therapy in multiple myeloma

Mené dans 16 pays sur 291 patients atteints d'un myélome multiple réfractaire ou récidivant, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du vénétoclax à un traitement combinant bortézomib et dexaméthasone (durée médiane de suivi : 18,7 mois)

Résumé en anglais

BCL2 was first discovered in the context of the t(14;18) translocation in follicular lymphoma, and many years of research have ensued to understand the role of this family of proapoptotic and antiapoptotic proteins in the survival of malignant cells. 1 Mimics of the small molecule BH3 (BID) were designed to competitively bind to antiapoptotic proteins and liberate the proapoptotic proteins to trigger apoptosis, especially in cells that are primed for death. Decades of drug discovery have led to the development and regulatory approval of the first of these drugs, venetoclax, a selective BCL-2 inhibitor